Showing results (191-200 of 345) with videos related to

Sort By:
Pageof 35
Cancers|September 23, 2022
Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid CancerDavide Saronni, Germano Gaudenzi, Alessandra Dicitore, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2019
Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro StudySara G Creemers, Richard A Feelders, Frank H de Jong, et al.
Biomedicines|March 25, 2022
The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System ActivationAmber Blaauboer, Peter M van Koetsveld, Dana A M Mustafa, et al.
Clinical Endocrinology|December 1, 1996
In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligandW W de Herder, A E Reijs, D J Kwekkeboom, et al.
Endocrine-Related Cancer|May 4, 2023
Unfavorable biological behavior and treatment response of neuroendocrine ovarian metastases of midgut neuroendocrine tumorsM C F Mulders, Q G de Lussanet de la Sablonière, M L F van Velthuysen, et al.
Neuroendocrinology|October 19, 2020
Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical StudyAlessandra Dicitore, Maria Celeste Cantone, Germano Gaudenzi, et al.
Cancer Research|January 7, 2006
IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitroGiovanni Vitale, Wouter W de Herder, Peter M van Koetsveld, et al.
Current Cancer Drug Targets|June 11, 2009
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathwaysM Caraglia, M Marra, P Tagliaferri, et al.
Journal of Endocrinological Investigation|December 17, 1998
A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysisA M Alings, E Fliers, W W de Herder, et al.
Pageof 35